Apolipoprotein B Is Related to Metabolic Syndrome Independently of Low Density Lipoprotein Cholesterol in Patients with Type 2 Diabetes

被引:22
作者
Lim, Younghyup [1 ]
Yoo, Soyeon [1 ]
Lee, Sang Ah [1 ,2 ]
Chin, Sang Ouk [1 ]
Heo, Dahee [1 ]
Moon, Jae Cheol [1 ]
Moon, Shinhang [1 ]
Boo, Kiyoung [1 ]
Kim, Seong Taeg [1 ]
Seo, Hye Mi [1 ]
Jwa, Hyeyoung [1 ]
Koh, Gwanpyo [1 ,2 ]
机构
[1] Jeju Natl Univ Hosp, Dept Internal Med, Jeju, South Korea
[2] Jeju Natl Univ, Sch Med, Dept Internal Med, 15 Aran 13 Gil, Jeju 690767, South Korea
关键词
Diabetes mellitus; type; 2; Apolipoproetin B; Metabolic syndrome; Cardiovascular diseases;
D O I
10.3803/EnM.2015.30.2.208
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Increased low density lipoprotein cholesterol (LDL-C) level and the presence of metabolic syndrome (MetS) are important risk factors for cardiovascular disease (CVD) in type 2 diabetes mellitus (T2DM). Recent studies demonstrated apolipoprotein B (apoB), a protein mainly located in LDL-C, was an independent predictor of the development of CVD especially in patients with T2DM. The aim of this study was to investigate the relationship between apoB and MetS in T2DM patients. Methods: We analyzed 912 patients with T2DM. Fasting blood samples were taken for glycated hemoglobin, high-sensitivity Creactive protein, total cholesterol, triglyceride (TG), high density lipoprotein cholesterol, LDL-C, and apoB. MetS was defined by the modified National Cholesterol Education Program Adult Treatment Panel III criteria. We performed a hierarchical regression analysis with apoB as the dependent variable. Age, sex, the number of components of MetS and LDL-C were entered at model 1, the use of lipid-lowering medications at model 2, and the individual components of MetS were added at model 3. Results: Seventy percent of total subjects had MetS. ApoB level was higher in subjects with than those without MetS (104.5 +/- 53.3 mg/dL vs. 87.7 +/- 33.7 mg/dL, P<0.01) even after adjusting for LDL-C. ApoB and LDL-C were positively correlated to the number of MetS components. The hierarchical regression analysis showed that the increasing number of MetS components was associated with higher level of apoB at step 1 and step 2 (beta = 0.120, P< 0.001 and beta = 0.110, P< 0.001, respectively). At step 3, TG (beta=0.116, P< 0.001) and systolic blood pressure (beta=0.099, P<0.05) were found to significantly contribute to apoB. Conclusion: In patients with T2DM, apoB is significantly related to MetS independently of LDL-C level. Of the components of MetS, TG, and systolic blood pressure appeared to be determinants of apoB.
引用
收藏
页码:208 / 215
页数:8
相关论文
共 38 条
[1]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[2]  
2-S
[3]   Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans [J].
Anber, V ;
Millar, JS ;
McConnell, M ;
Shepherd, J ;
Packard, CJ .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (11) :2507-2514
[4]  
Assmann G, 1998, EUR HEART J, V19, pA2
[5]  
AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917
[6]   Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy [J].
Boden, William E. ;
Probstfield, Jeffrey L. ;
Anderson, Todd ;
Chaitman, Bernard R. ;
Desvignes-Nickens, Patrice ;
Koprowicz, Kent ;
McBride, Ruth ;
Teo, Koon ;
Weintraub, William .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (24) :2255-2267
[7]   The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study [J].
Bonora, E ;
Targher, G ;
Formentini, G ;
Calcaterra, F ;
Lombardi, S ;
Marini, F ;
Zenari, L ;
Saggiani, F ;
Poli, M ;
Perbellini, S ;
Raffaelli, A ;
Gemma, L ;
Santi, L ;
Bonadonna, RC ;
Muggeo, M .
DIABETIC MEDICINE, 2004, 21 (01) :52-58
[8]   Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study [J].
Bruno, G ;
Merletti, F ;
Biggeri, A ;
Bargero, G ;
Prina-Cerai, S ;
Pagano, G ;
Cavallo-Perin, P .
DIABETOLOGIA, 2006, 49 (05) :937-944
[9]   THE TRIGLYCERIDE ISSUE - A VIEW FROM FRAMINGHAM [J].
CASTELLI, WP .
AMERICAN HEART JOURNAL, 1986, 112 (02) :432-437
[10]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497